Carbamazepine and Its -10,11-Epoxide Metabolite in Plasma and CSF
- 1 June 1983
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of General Psychiatry
- Vol. 40 (6) , 673-676
- https://doi.org/10.1001/archpsyc.1983.04390010083010
Abstract
• Levels of carbamazepine and its -10,11-epoxide metabolite were measured in plasma and CSF of affectively ill patients treated only with carbamazepine for an average of 33 days at an average dosage of 1,055 mg/day. The CSF levels of carbamazepine were 2.06 μ/mL (ie, 31% of plasma levels, which equaled 6.55 μ/mL); CSF -10,11-epoxide concentrations averaged 0.91 μ/mL in 18 subjects (63% of those found in plasma). Carbamazepine levels in plasma or CSF were not related to degree of antidepressant or antimanic response. In contrast, concentrations of the -10,11-epoxide metabolite were correlated with the degree of antidepressant response. This preliminary study suggests the possibility that the -10,11-epoxide metabolite of carbamazepine may be related to the degree of clinical efficacy in affectively ill patients and may thus possess active psychotropic properties in man in addition to its reported anticonvulsant effects in animals. (Arch Gen Psychiatry1983;40:673-676)Keywords
This publication has 5 references indexed in Scilit:
- INFLUENCE OF PHENOBARBITAL AND DIPHENYLHYDANTOIN ON PLASMA CARBAMAZEPINE LEVELS IN PATIENTS WITH EPILEPSYActa Neurologica Scandinavica, 2009
- Carbamazepine, carbamazepine-10,11-epoxide and phenytoin concentrations in brain tissue of epileptic childrenActa Neurologica Scandinavica, 2009
- Clinical Pharmacokinetics of CarbamazepineClinical Pharmacokinetics, 1978
- INTERACTION OF PROPOXYPHENE WITH CARBAMAZEPINEThe Lancet, 1977
- Kinetics of carbamazepine and its 10,11‐epoxide metabolite in childrenClinical Pharmacology & Therapeutics, 1976